During my 25 years at the Food and Drug Administration, I had a front-row seat for the evolution and modernization of pharmaceutical research. Now that I’m in the private sector, I’m discouraged to see political candidates bash drug companies for easy applause lines.
When policies affecting the development of new treatments are reduced to sound bites, the future of medical innovation is put in jeopardy. The debate over the federal government’s so-called “march-in” rights regarding prescription drugs is a perfect example of this danger.
Read Full Article »